Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).
about
Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.Natural product and natural product derived drugs in clinical trials.Emerging drugs for endometrial cancer.Drug delivery and release systems for targeted tumor therapy.GnRH and GnRH receptors in the pathophysiology of the human female reproductive system.Controlling toxicity of Peptide-drug conjugates by different chemical linker structures.The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and MetastasisNew therapies for advanced, recurrent, and metastatic endometrial cancers.A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids
P2860
Q34101055-729839F3-F1B5-4524-BC7A-069B5868C1C1Q34894406-FFDF8EEE-2F18-490D-9115-B2EC90FF4375Q37034254-F7652B4C-BD5A-46A2-92AA-34C412B227AFQ38247457-BC5844B0-B4B3-458A-8145-00B2D3249AB6Q38261469-491B76F6-193C-4894-A6D1-A482DABA7165Q38363691-56F9FD96-235F-470E-8278-70B4134B6CE4Q38682630-421E3274-854E-4C1E-A8A9-CFC993251532Q38882129-5C9BF8B0-F6EC-40B1-9B93-66F722ACF2D2Q41242658-107A15C3-9B33-4234-95BF-3C3431DA9D5DQ47103210-C7D9356C-D95B-49BF-ACCD-25AB7BC86DF6Q47369407-AB012FD6-9F0B-4C8E-9B42-0CFA9112014FQ55054276-F0C2C1E6-FBB1-4FB8-B031-FCA570C87BEBQ57821212-92F2FB53-CC4C-49DF-BD60-F209F5467520
P2860
Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of AEZS-10 ...... nter phase 2 trial (AGO-GYN5).
@ast
Efficacy and safety of AEZS-10 ...... nter phase 2 trial (AGO-GYN5).
@en
Efficacy and safety of AEZS-108
@nl
type
label
Efficacy and safety of AEZS-10 ...... nter phase 2 trial (AGO-GYN5).
@ast
Efficacy and safety of AEZS-10 ...... nter phase 2 trial (AGO-GYN5).
@en
Efficacy and safety of AEZS-108
@nl
prefLabel
Efficacy and safety of AEZS-10 ...... nter phase 2 trial (AGO-GYN5).
@ast
Efficacy and safety of AEZS-10 ...... nter phase 2 trial (AGO-GYN5).
@en
Efficacy and safety of AEZS-108
@nl
P2093
P2860
P50
P1476
Efficacy and safety of AEZS-10 ...... nter phase 2 trial (AGO-GYN5).
@en
P2093
Anne Stähle
Carsten Gründker
Felix Hilpert
Grigor Gorchev
Günter Emons
Herbert Sindermann
Lars Hanker
Peter Dall
Philipp Harter
P2860
P304
P356
10.1097/IGC.0000000000000044
P577
2014-02-01T00:00:00Z